The federal litigation of Byetta lawsuits (http://www.byettalawsuit.com/) and other claims involving similar Type 2 diabetes drugs has grown to include more than 300 cases, Bernstein Liebhard LLP reports.
According to a Case List updated February 19th by the U.S. Judicial Panel on Multidistrict Litigation (JPML), a total of 306 claims have now been filed in a proceeding underway in the U.S. District Court, Southern District of California. Plaintiffs in these lawsuits, which involve a class of Type 2 diabetes medications referred to as incretin mimetics, similarly allege that the manufacturers of Januvia, Victoza and other products failed to warn about their association with pancreatitis, pancreatic cancer and other side effects. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
“Our Firm continues to hear from individuals who may have developed pancreatitis or pancreatic cancer after taking Byetta, so we are not surprised to see the federal litigation continuing to move forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is actively offering free and confidential case evaluations to individuals who took the Type 2 diabetes drug, Byetta, and were later diagnosed with pancreatic cancer, pancreatitis or thyroid cancer.
Byetta Pancreatic Cancer Lawsuits
Court documents indicate that in only a few short months, the federal Type 2 diabetes drug litigation has seen a substantial increase in its number of Byetta pancreatic cancer lawsuits, as well as claims over Victoza, Januvia and other medications. The JPML’s last Case List update on January 15th, for example, showed a total of 262 cases pending in the litigation, compared to more than 300 that have now been filed.
According to court records, there have also been a number of recent Byetta lawsuit updates in the proceeding. On February 10th, a Memorandum submitted to the California court proposed a plan from the defense that would require plaintiffs to file general causation expert reports in less than 90 days, before the completion of discovery related to the design and research of the medications. A brief filed on behalf of plaintiffs the same day argued against the proposal, asserting that 90 days is too short an amount of time for plaintiffs to fully investigate the case and select appropriate experts.
All federal lawsuits involving Byetta and other similar drugs follow a March 2013 announcement from the U.S. Food and Drug Administration (FDA) that addressed the possible dangers associated with incretin mimetics. The public health alert was issued after a previously unpublished study found users of the medications to be at an increased risk of experiencing precancerous cellular changes to the pancreas. The FDA vowed to investigate the safety of Byetta, Januvia and other medications at this time.
Diabetics taking Byetta who may have been harmed by the drug may be eligible to file a claim against its manufacturer. Learn more about the possible association between Byetta and pancreatic cancer, pancreatitis and thyroid cancer at Bernstein Liebhard LLP’s website. For a free case evaluation, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Comments are closed.